Abstract
European integration in the pharmaceutical market is characterized by unequal progress. Achieved tradability and retained national price controls resulted in parallel trade for pharmaceuticals. The paper explains the processes and the outcomes of a long term negotiation process among member states, EU Commission and the pharmaceutical industry. The paper derives the constellation of preferences, analyzes the negotiation situation and explains the persisting deadlock, in which persisting divergence of preferences among the actors involved obstructed any political solution. As a clear case in point of Tsebelis' theoretical argument, this disagreement enabled the European Court of Justice to act as a stand-in policy maker. With its judgments, the court is setting a de-integration solution, which is tolerated by all po- litical actors, albeit they could not agree on this policy in the negotiations. The solution set is likely to be stable, because there is no consensus to revoke it.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
